首页    期刊浏览 2024年07月08日 星期一
登录注册

文章基本信息

  • 标题:Adaptive oncology phase I trial design of drug combinations with drug-drug interaction modeling
  • 作者:Yang, Yang ; Fang, Hong-Bin ; Roy, Anindya
  • 期刊名称:Statistics and Its Interface
  • 印刷版ISSN:1938-7989
  • 电子版ISSN:1938-7997
  • 出版年度:2018
  • 卷号:11
  • 期号:1
  • 页码:109-127
  • DOI:10.4310/SII.2018.v11.n1.a10
  • 语种:English
  • 出版社:International Press
  • 摘要:The goal of a Phase I trial is to find the maximum tolerated dose (MTD). In a single-agent dose finding Phase I trial, the key underlying assumption is that toxicity probability increases monotonically with the dose level. However, in multi-agent trials, this assumption may not hold because the drug-drug interaction potentially can either decrease or increase the joint toxicity as compared to either one used alone, which may lead to an unforeseen toxicity probability surface. Thus there exists multiple MTDs. We first develop a novel adaptive dose-finding approach which can be applied to these kinds of multi-drug combination trials. With this approach, drug-drug interaction and toxicity probability are modeled jointly through a Bliss independence model. The main goal of our dose finding scheme is to search for maximum tolerated region (MTR), as opposed to maximum tolerated dose (MTD), in single agent phase I trials. The method allows exploration of more combinations in the phase I stage, which is of particular relevance in oncology since phase I trials on the combinations may be the only opportunity before launching a costly phase III trial, comparing selected combination(s) with a standard of care. Dose escalation/de-escalation decision rules are determined by the posterior estimates of both joint toxicity probability and the corresponding drug-drug interaction, which can be continuously updated by sequentially assigning new patients into the trial while more data is being observed. We evaluate the operating characteristics of the proposed method through extensive simulation studies under various scenarios. The proposed method demonstrates satisfactory performance. In addition, the MTR offers several combinations that investigators may choose to advance to future trials based on external information from e.g., preclinical antitumor activities and other trials.
  • 关键词:adaptive Bayesian design; bliss independence; drug combination; dose finding; interaction index function; maximum tolerated dose (MTD); maximum tolerated region; objective function
Loading...
联系我们|关于我们|网站声明
国家哲学社会科学文献中心版权所有